By Katherine Hamilton
Solid Biosciences received clearance from the Food and Drug Administration for an investigational new drug application, the company said Tuesday.
The application is for SGT-212, designed to treat the degenerative disease Friedreich's ataxia. The drug is unique because it uses two routes of administration to address the illness in the cardiac region and the cerebellum.
The Charlestown, Mass.-based company expects to initiate a phase 1b clinical trial in the second half of 2025.
Shares climbed 20% to $4.70 in after-hours trading following the news.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(MORE TO FOLLOW) Dow Jones Newswires
January 07, 2025 16:40 ET (21:40 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。